The use of AI will transform patient outcomes, report finds
A recent report by Juniper Research has stated that not only will AI transform and shape the role in which digitisation will play within healthcare sector, the total spending on CAD (computer aided diagnosis) systems will reach $800.7 million by 2022.
It also adds that “by 2022, 28.4 million chronic disease scans will also be fed into first-line CAD systems annually.”
Large volumes of data routinely inputted into healthcare systems and Electronic Health Records (EHRs) will ultimately be harnessed in a bid to improve and provide exceptional patient centered care, as well as create an element of convenience with patients through implementing online booking systems, and the ability to speak to a medical professional, anytime, anywhere.
- NowRx aims to disrupt the pharmacy market
- President Trump begins to break up the Affordable Healthcare Act to increased public outcry
- Pfizer is looks to sell its consumer healthcare business, pharma competitors
The implementation of CAD systems will also provide the ability to look at certain trends within a number of chronic conditions through the use of diagnostics, and consequently lower costs across the board and enable acute healthcare settings to provide higher quality treatment options.
Nonetheless, with recent worldwide cyber-security attacks, such as the WannaCry attack involving the National Health Service in the United Kingdom, the need for IT infrastructures and cloud systems remains paramount within any risk analysis taken.
Current healthcare regulations under the European Union are consequently being revised, as well as the General Data Protection Regulation, which will become more specific and provide a more robust set of processes which businesses will need to follow.
Skin Analytics wins NHSX award for AI skin cancer tool
An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system.
NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion.
Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making.
In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog.
Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening.
DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.
Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.
Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges.
"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”